These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 25998502)

  • 1. Discovery of LRRK2 inhibitors using sequential in silico joint pharmacophore space (JPS) and ensemble docking.
    Lang CA; Ray SS; Liu M; Singh AK; Cuny GD
    Bioorg Med Chem Lett; 2015 Jul; 25(13):2713-9. PubMed ID: 25998502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S.
    Liu M; Bender SA; Cuny GD; Sherman W; Glicksman M; Ray SS
    Biochemistry; 2013 Mar; 52(10):1725-36. PubMed ID: 23379419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leucine-rich repeat kinase 2 mutants I2020T and G2019S exhibit altered kinase inhibitor sensitivity.
    Reichling LJ; Riddle SM
    Biochem Biophys Res Commun; 2009 Jun; 384(2):255-8. PubMed ID: 19397894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor.
    Reith AD; Bamborough P; Jandu K; Andreotti D; Mensah L; Dossang P; Choi HG; Deng X; Zhang J; Alessi DR; Gray NS
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5625-9. PubMed ID: 22863203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).
    Deng X; Choi HG; Buhrlage SJ; Gray NS
    Expert Opin Ther Pat; 2012 Dec; 22(12):1415-26. PubMed ID: 23126385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triazolopyridazine LRRK2 kinase inhibitors.
    Franzini M; Ye XM; Adler M; Aubele DL; Garofalo AW; Gauby S; Goldbach E; Probst GD; Quinn KP; Santiago P; Sham HL; Tam D; Truong A; Ren Z
    Bioorg Med Chem Lett; 2013 Apr; 23(7):1967-73. PubMed ID: 23454015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of 4-alkylamino-7-aryl-3-cyanoquinoline LRRK2 kinase inhibitors.
    Garofalo AW; Adler M; Aubele DL; Brigham EF; Chian D; Franzini M; Goldbach E; Kwong GT; Motter R; Probst GD; Quinn KP; Ruslim L; Sham HL; Tam D; Tanaka P; Truong AP; Ye XM; Ren Z
    Bioorg Med Chem Lett; 2013 Apr; 23(7):1974-7. PubMed ID: 23453068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of LRRK2 inhibitors by using an ensemble of virtual screening methods.
    Gancia E; De Groot M; Burton B; Clark DE
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2520-2527. PubMed ID: 28408230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor.
    Henderson JL; Kormos BL; Hayward MM; Coffman KJ; Jasti J; Kurumbail RG; Wager TT; Verhoest PR; Noell GS; Chen Y; Needle E; Berger Z; Steyn SJ; Houle C; Hirst WD; Galatsis P
    J Med Chem; 2015 Jan; 58(1):419-32. PubMed ID: 25353650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffold.
    Galatsis P; Henderson JL; Kormos BL; Han S; Kurumbail RG; Wager TT; Verhoest PR; Noell GS; Chen Y; Needle E; Berger Z; Steyn SJ; Houle C; Hirst WD
    Bioorg Med Chem Lett; 2014 Sep; 24(17):4132-40. PubMed ID: 25113930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unique functional and structural properties of the LRRK2 protein ATP-binding pocket.
    Liu Z; Galemmo RA; Fraser KB; Moehle MS; Sen S; Volpicelli-Daley LA; DeLucas LJ; Ross LJ; Valiyaveettil J; Moukha-Chafiq O; Pathak AK; Ananthan S; Kezar H; White EL; Gupta V; Maddry JA; Suto MJ; West AB
    J Biol Chem; 2014 Nov; 289(47):32937-51. PubMed ID: 25228699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a high-throughput AlphaScreen assay measuring full-length LRRK2(G2019S) kinase activity using moesin protein substrate.
    Pedro L; Padrós J; Beaudet L; Schubert HD; Gillardon F; Dahan S
    Anal Biochem; 2010 Sep; 404(1):45-51. PubMed ID: 20434426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indolinone based LRRK2 kinase inhibitors with a key hydrogen bond.
    Göring S; Taymans JM; Baekelandt V; Schmidt B
    Bioorg Med Chem Lett; 2014 Oct; 24(19):4630-4637. PubMed ID: 25219901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel cinnoline-based inhibitors of LRRK2 kinase activity.
    Garofalo AW; Adler M; Aubele DL; Bowers S; Franzini M; Goldbach E; Lorentzen C; Neitz RJ; Probst GD; Quinn KP; Santiago P; Sham HL; Tam D; Truong AP; Ye XM; Ren Z
    Bioorg Med Chem Lett; 2013 Jan; 23(1):71-4. PubMed ID: 23219325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ATP-competitive LRRK2 inhibitors interfere with monoclonal antibody binding to the kinase domain of LRRK2 under native conditions. A method to directly monitor the active conformation of LRRK2?
    Gillardon F; Kremmer E; Froehlich T; Ueffing M; Hengerer B; Gloeckner CJ
    J Neurosci Methods; 2013 Mar; 214(1):62-8. PubMed ID: 23318290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a mechanism-based high-throughput screen assay for leucine-rich repeat kinase 2--discovery of LRRK2 inhibitors.
    Liu M; Poulose S; Schuman E; Zaitsev AD; Dobson B; Auerbach K; Seyb K; Cuny GD; Glicksman MA; Stein RL; Yue Z
    Anal Biochem; 2010 Sep; 404(2):186-92. PubMed ID: 20566370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design.
    Ray S; Liu M
    Future Med Chem; 2012 Sep; 4(13):1701-13. PubMed ID: 22924508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The development of CNS-active LRRK2 inhibitors using property-directed optimisation.
    Kavanagh ME; Doddareddy MR; Kassiou M
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3690-6. PubMed ID: 23721803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the functional impact of mutational drift in LRRK2 gene and identification of specific inhibitors for the treatment of Parkinson disease.
    Nagarajan N; Chellam J; Kannan RR
    J Cell Biochem; 2018 Jun; 119(6):4878-4889. PubMed ID: 29369408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
    Kethiri RR; Bakthavatchalam R
    Expert Opin Ther Pat; 2014 Jul; 24(7):745-57. PubMed ID: 24918198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.